Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.33 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28066668 | 1.00 | PDE4A (0.61) | PDE4ALMNAL3MBTL1USP2SLCO1B1 | |
| SCHEMBL378867 | 1.00 | PDE4A (0.61) | PDE4ALMNAL3MBTL1USP2SLCO1B1 | |
| SCHEMBL6234202 | 0.98 | PDE4A (0.59) | PDE4ALMNAL3MBTL1USP2SLCO1B1 | |
| SCHEMBL9576619 | 0.98 | PDE4A (0.59) | PDE4ALMNAL3MBTL1USP2SLCO1B1 | |
| SCHEMBL15453928 | 0.93 | PDE4A (0.52) | PDE4ALMNAL3MBTL1USP2SLCO1B1 | |
| SCHEMBL1129690 | 0.93 | PDE4A (0.52) | PDE4ALMNAL3MBTL1USP2SLCO1B1 | |
| SCHEMBL8218436 | 0.93 | PDE4A (0.52) | PDE4ALMNAL3MBTL1USP2SLCO1B1 | |
| SCHEMBL14124935 | 0.84 | PDE4A (0.44) | PDE4ALMNAL3MBTL1USP2SLCO1B1 | |
| SCHEMBL27216229 | 0.84 | PDE4A (0.44) | PDE4ALMNAL3MBTL1USP2SLCO1B1 | |
| SCHEMBL1635580 | 0.83 | LMNA (0.59) | PDE4ALMNAL3MBTL1USP2SLCO1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6503885-B1 | Selectin inhibitors; anticarcinogenic, antiinflammatory, and antimetastasis agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2003-01-07 | — | — | US | claimed |
| US-12187817-B2 | Preparation of ceramide conjugates and derivatives of sphingolipid analogues | KODE BIOTECH LIMITED (NZ) | 2025-01-07 | — | — | US | disclosed |
| US-20230374076-A1 | THE PREPARATION OF CERAMIDE CONJUGATES AND DERIVATIVES OF SPHINGOLIPID ANALOGUES | KODE BIOTECH LIMITED (NZ) | 2023-11-23 | — | — | US | disclosed |
| US-11760779-B2 | Preparation of ceramide conjugates and derivatives of sphingolipid analogues | KODE BIOTECH LIMITED (NZ) | 2023-09-19 | — | — | US | disclosed |
| US-20210214396-A1 | THE PREPARATION OF CERAMIDE CONJUGATES AND DERIVATIVES OF SPHINGOLIPID ANALOGUES | KODE BIOTECH LIMITED (NZ) | 2021-07-15 | — | — | US | disclosed |
| WO-2018220603-A1 | THE PREPARATION OF CERAMIDE CONJUGATES AND DERIVATIVES OF SPHINGOLIPID ANALOGUES | BOVIN NICOLAI VLADIMIROVICH (RU) | 2018-12-06 | — | — | WO | disclosed |
| US-6503885-B1 | Selectin inhibitors; anticarcinogenic, antiinflammatory, and antimetastasis agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2003-01-07 | — | — | US | disclosed |
| US-6503885-B1 | Selectin inhibitors; anticarcinogenic, antiinflammatory, and antimetastasis agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2003-01-07 | — | — | US | disclosed |
| US-6503885-B1 | Selectin inhibitors; anticarcinogenic, antiinflammatory, and antimetastasis agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2003-01-07 | — | — | US | disclosed |
| WO-2000017216-A1 | CARBOXYMETHYLGALACTOSE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2000-03-30 | — | — | WO | disclosed |
| EP-0929562-A1 | ACID-FUNCTIONALIZED SACCHARIDES AS POLYVALENT ANTI-INFECTIVES | GELTEX PHARMACEUTICALS, INC. (US) | 1999-07-21 | — | — | EP | disclosed |
| US-5821312-A | Acid-functionalized saccharides as polyvalent anti-infectives | GELTEX PHARMACEUTICALS, INC. (US) | 1998-10-13 | — | — | US | disclosed |
| WO-1998012203-A1 | ACID-FUNCTIONALIZED SACCHARIDES AS POLYVALENT ANTI-INFECTIVES | GELTEX PHARMACEUTICALS, INC. (US) | 1998-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374076-A1 | THE PREPARATION OF CERAMIDE CONJUGATES AND DERIVATIVES OF SPHINGOLIPID ANALOGUES | SGMS1, SGMS2, CERT1 | PDE4A 3915/4885LMNA 76/4885L3MBTL1 1439/4885 |
| US-11760779-B2 | Preparation of ceramide conjugates and derivatives of sphingolipid analogues | SGMS1, SGMS2, CERT1 | PDE4A 3784/4885LMNA 107/4885L3MBTL1 1635/4885 |
| US-20210214396-A1 | THE PREPARATION OF CERAMIDE CONJUGATES AND DERIVATIVES OF SPHINGOLIPID ANALOGUES | SGMS1, SGMS2, CERT1 | PDE4A 3955/4885LMNA 77/4885L3MBTL1 1405/4885 |
| US-12187817-B2 | Preparation of ceramide conjugates and derivatives of sphingolipid analogues | SGMS1, SGMS2, CERT1 | PDE4A 3770/4885LMNA 113/4885L3MBTL1 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.